Conference Programme

You will find the preliminary programme of the conference on February, 24th here. 

Time Title
09:00 – 09:30 Registration
09:30 – 09:45 Welcome address
Sir Sebastian Wood KCMG, British Ambassador to Germany
Keynote Session
09:45 – 10:10 Keynote: The Global AMR Innovation Fund
Christopher Egerton-Warburton, Fund Manager and Founding Partner of Lion's Head Global Partner and Member of Expert Advisory Bord, Global AMR Innovation Fund 
10:10 – 10:30 Stimulating innovation: novel approaches to incentivising antibacterial R&D
David Findlay, Deputy Coordinator Drive-AB/GSK, UK
10:30 – 10:50

Funding the research and development of novel antibiotics:  the perspective of a startup company
Nicholas Benedict, Co-Founder & CEO, Allecra, GER

10:50 – 11:10 Coffee Break
Session "Market access in the era of AMR - bringing ideas to the patients"

Session “SMEs to tackle AMR”

Chair: Philippe Villain-Guillot, CEO, Nosopharm

- Leonie de Best, CBO, Madam Therapeutics, NL
- Philippe Villain-Guillot, CEO, Nosopharm
- Nicola Thompson, CBO, PhicoTherapeutics, UK
- Marc Lemonnier, CEO, Antabio, F
- Thomas Kapsner, CEO Morphochem, GER

11:10 – 11:40 IP & Regulation: Patent strategies to meet the challenge
of AMR
Ute Kilger (Partner) & Heinz Goddar (Partner), Boehmert & Boehmert, GER
11:40 – 12:00 From bench to bedside: Developing new drugs for bad bugs on a European scale, Anders Karlén, University of Uppsala, SE and Managing Coordinator, ENABLE consortium
12:00 – 12:20

Clinical decision making: The relevance of new methods for antimicrobial susceptibility testing, Hajo Grundmann, University of Groningen, Member of EUCAST Subcommittee, NL

12:20 – 12:50

Panel discussion – How to overcome the bottlenecks in the AMR field?

Christopher Egerton-Warburton, Member of Expert Advisory Bord, Global AMR Innovation Fund 
Andrew Ullmann, University of Würzburg
Ute Kilger, Boehmert & Boehmert
Hajo Grundmann, University of Groningen

12:50 – 13:40 Lunch Break
Session “How to create a business case with antimicrobials”

Session: Think beyond – technology highlights from academic research

Chair: Andrew Ullmann, University of Würzburg

- Yves Briers, Ghent University, BE
- Stephan Sieber, Technical University Munich, GER
- Michael McDonough, University of Oxford, UK
- Mark Brönstrup, Helmholtz Centre for Infection Research, GER
- Andreas Peschel, University of Tübingen, GER
- Aras Kadioglu, University of Liverpool, UK

 

13:40 – 14:00 Accelerating the antibiotics pipeline: CARB-X and AMRC 
Peter Jackson, steering group chairman, AMR centre, UK
14:00 – 14:20 Reliability of antibiotics supply in Germany –  Effect of supplier consolidation
Morris Hosseini, Roland Berger, GER
14:20 – 14:40

The SME perspective 
Marie Petit, Coordinator, BEAM Alliance
Marc Gitzinger, CEO, BioVersys, CH

14:40 – 15:40

Technology Highlights

Rasmus Toft-Kehler, CEO, AntibioTx, DK
Deborah O’Neil, CEO & CSO, NovaBiotics, UK
Frauke Hein, CBO, Adrenomed AG, GER 

15:40 – 16:10 Coffee Break
Session “Start-up competition & investors talk”
16:10 – 16:40

Investors talk – Panel Discussion: Developing new antimicrobial agents - a business case for start-ups?
Holger Reithinger, Partner, Forbion Capital Partners, GER/NL
Marc Gitzinger, CEO, BioVersys, CH
Rasmus Toft-Kehler, CEO, AntibioTx, DK
Olivier Litzka, Partner, Edmond de Rothschild, F

16:40 – 17:20

Start-up pitch: Start-up presentations and award
Auspherix, UK
Immunethep, P
Juvabis, CH
QureTech Bio, S
Omnix Medical, ISR 

17:20 – 17:40 Open discussion and wrap-up: The future of antiinfective R&D
17:40 – 19:00 Networking & reception

Moderator: Peter West, CEO, Academy of Infection Management (AIM)